The single-molecule real-time (SMRT) sequencing market is experiencing rapid growth as researchers and healthcare providers increasingly adopt long-read sequencing technologies to unlock deeper insights into complex genomes. Valued at USD 2.92 billion in 2025, the market is projected to reach USD 5.32 billion by 2030, growing at a CAGR of 12.8% during the forecast period.
Unlike conventional short-read sequencing technologies, SMRT sequencing enables scientists to generate highly accurate long reads that improve the detection of structural variants, repetitive DNA regions, and complex genomic rearrangements. As precision medicine, rare disease diagnostics, cancer genomics, and agricultural biotechnology continue to evolve, SMRT sequencing is becoming an indispensable tool for comprehensive genomic analysis.
Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=161993235
Growing Demand for High-Accuracy Long-Read Sequencing
The increasing need for accurate genome assembly and comprehensive variant detection is one of the primary factors driving the SMRT sequencing market. Researchers are seeking technologies capable of resolving challenging genomic regions that are difficult to analyze using short-read sequencing alone.
SMRT sequencing offers significant advantages, including:
- High-fidelity (HiFi) long reads
- Improved structural variant detection
- Better genome assembly accuracy
- Enhanced analysis of repetitive genomic regions
- Comprehensive haplotype phasing
These capabilities are accelerating adoption across academic research institutions, clinical laboratories, pharmaceutical companies, and biotechnology organizations worldwide.
Strategic Collaborations Accelerating Innovation
Industry leaders are increasingly forming strategic partnerships to expand sequencing capabilities and improve workflow efficiency.
A notable example is the June 2025 collaboration between PacBio and Ultima Genomics, aimed at combining PacBio’s highly accurate SMRT long-read technology with Ultima’s cost-efficient short-read sequencing platform. The partnership seeks to develop scalable sequencing solutions for large population studies, clinical research, and precision medicine initiatives, providing researchers with both accuracy and affordability.
Such collaborations are expected to accelerate technological innovation while making advanced sequencing more accessible across diverse research applications.
Key Companies Strengthening the Competitive Landscape
Several leading life science companies continue to shape the SMRT sequencing ecosystem through technological innovation, product development, and strategic expansion.
PacBio (US) remains the technology leader in dedicated SMRT sequencing, continuously advancing its HiFi sequencing platforms for applications in human genomics, oncology, microbiology, and rare disease research.
Illumina, Inc. (US) plays a complementary role by providing industry-leading short-read sequencing systems, including the NovaSeq and NextSeq platforms. Many research laboratories combine Illumina’s high-throughput sequencing with SMRT long-read data to achieve comprehensive genome assemblies and cost-effective population-scale studies.
Thermo Fisher Scientific, Inc. (US) supports the market through its extensive portfolio of sample preparation solutions, library preparation chemistries, automation systems, quality control instruments, and bioinformatics platforms. These technologies help laboratories standardize and optimize SMRT sequencing workflows while supporting integrated multi-omics research.
Agilent Technologies (US) contributes by offering advanced quality control and analytical instrumentation, including Bioanalyzer and Fragment Analyzer systems that ensure high-quality DNA libraries before sequencing. Its sample preparation and target enrichment technologies further improve workflow reliability and sequencing performance.
Other important participants include Eurofins Scientific (Luxembourg) and BGI Group (China), both expanding their genomics capabilities to support growing global demand.
Request Sample Pages@ https://www.marketsandmarkets.com/requestsampleNew.asp?id=161993235
Market Outlook
The SMRT sequencing market remains relatively consolidated, with established technology providers leveraging strategic partnerships, product innovation, and geographic expansion to strengthen their market positions.
As healthcare systems increasingly embrace precision medicine and researchers pursue more comprehensive genomic insights, demand for high-accuracy long-read sequencing will continue to grow. Hybrid sequencing approaches that combine long-read and short-read technologies are expected to become the industry standard, delivering superior genomic resolution while optimizing costs.
With continuous advances in sequencing chemistry, automation, bioinformatics, and multi-omics integration, the global SMRT sequencing market is well-positioned for sustained growth through 2030, supporting breakthroughs in clinical diagnostics, drug discovery, agricultural genomics, and personalized healthcare.
Inquire Before Buying@ https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=161993235